742027
Last Update Posted: 2021-07-28
Recruiting has ended
All Genders accepted | 18 Years + |
129 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat also was assessed. Other markers that may correlate with efficacy or safety were explored.
Eligibility
Relevant conditions:
Classical Hodgkin's Lymphoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov